Perimenopause Treatment Guidelines

Introduction to Perimenopause Management

The National Comprehensive Cancer Network recommends that the most effective treatment for perimenopausal symptoms is menopausal hormone therapy (MHT), though non-hormonal options should be considered first-line for most women due to safety considerations 1, 2

Evaluate for medical causes of symptoms such as thyroid disease and diabetes before attributing to perimenopause 2, 3
Laboratory evaluation may include estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin as clinically indicated 2, 4
Note that FSH is not a reliable marker of menopausal status in women with prior chemotherapy, pelvic radiation exposure, or those on tamoxifen 2, 3
For vaginal dryness complaints, a pelvic evaluation should assess for vaginal atrophy 2, 4

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) can effectively reduce vasomotor symptoms 2, 5
Caution with paroxetine in women taking tamoxifen due to CYP2D6 inhibition that may affect tamoxifen metabolism 2, 4
Anticonvulsants such as gabapentin and pregabalin have shown efficacy for vasomotor symptoms 2, 5
Certain antihypertensives like clonidine may help decrease hot flash intensity 6
Doses for managing vasomotor symptoms are typically lower than those used for depression or other primary indications 2, 4
Weight loss of ≥10% may help eliminate hot flash symptoms 7, 8
Smoking cessation can improve frequency and severity of hot flashes 7, 8
Limiting alcohol intake if it triggers hot flashes in individual women 7, 8
Cognitive behavioral therapy (CBT) can reduce the perceived burden of hot flashes 7, 8
Physical activity is recommended for overall health benefits, though evidence for direct improvement of vasomotor symptoms is limited 7, 8
Water-based lubricants and moisturizers are primary treatments for vaginal dryness 6, 9
Silicone-based products may last longer than water-based or glycerin-based products 6
Vaginal dilators or pelvic floor relaxation techniques may help with dyspareunia 6

MHT is the most effective treatment for vasomotor symptoms but carries risks that must be considered 1, 2
General recommendations:
- Combination estrogen and progestins for women with an intact uterus 1, 3
- Estrogen alone for women without a uterus 1, 3
Contraindications include:
- History of hormone-related cancers 1, 3
- History of abnormal vaginal bleeding 1, 3
- Active liver disease 1, 3
- Recent history of pregnancy 1, 3
Low-dose estrogen vaginal tablets or estradiol vaginal rings may be recommended for vaginal dryness due to urogenital atrophy 6, 9
Results typically take 6-12 weeks to become apparent 6
Safety in women with a history of breast cancer is not well established 6
Not recommended for women on aromatase inhibitors 6
For young women experiencing perimenopause at an early age, oral contraceptives may provide symptom relief 1, 3

If MHT is used, appropriate specialist management of dosing is recommended 1, 3
Custom-compounded bioidentical hormones have no data supporting claims of being safer or more effective than standard hormone therapies 1, 3
For women with a history of breast cancer, non-hormonal options are strongly preferred 6, 9
Tibolone (where available) may improve sexual function more effectively than standard hormone therapy but is contraindicated in hormone-dependent cancers 9

The American College of Obstetricians and Gynecologists recommends assessing the frequency and severity of hot flashes and night sweats, as well as their impact on daily activities, in perimenopausal women with bothersome symptoms 10, 11
Approximately 50% of postmenopausal women experience genitourinary symptoms such as vaginal dryness, dyspareunia, and urinary symptoms, which will not resolve without treatment, according to the North American Menopause Society 10, 11
Women taking tamoxifen or aromatase inhibitors may experience worsened menopausal symptoms, and treatment options may be limited, as noted by the American Society of Clinical Oncology 10, 11
The use of venlafaxine and other SNRIs is preferred for managing vasomotor symptoms in women with contraindications to hormones, as recommended by the Endocrine Society 10, 11
The LIBERATE trial showed that tibolone was not equivalent to placebo and had safety concerns, leading to its halt, as reported by the European Menopause and Andropause Society 10

Cognitive behavioral therapy (CBT) reduces the perceived burden of hot flashes and may help with concentration difficulties, as recommended by the National Comprehensive Cancer Network 12
Venlafaxine, a preferred first-line pharmacologic agent, reduces hot flashes by approximately 60% and is effective for vasomotor symptoms at doses lower than those used for depression, with a faster onset of action compared to alternatives 12
Gabapentin decreases hot flash severity score by 46% compared to 15% with placebo, and is particularly useful when given at bedtime due to sedating effects, which can help with sleep disruption from night sweats 12
Clonidine can reduce hot flash frequency and severity, but has more side effects and appears less effective than venlafaxine 12, 13

The American College of Obstetricians and Gynecologists and other guideline societies recommend menopausal hormone therapy as the most effective treatment for vasomotor symptoms if non-hormonal approaches fail, with the lowest effective dose and for the shortest duration necessary 13
For women with intact uterus, combination estrogen plus progestogen should be used to protect the endometrium, as recommended by the American College of Obstetricians and Gynecologists 13

Acupuncture shows equivalence or superiority to venlafaxine or gabapentin for vasomotor symptoms, according to the National Comprehensive Cancer Network 12
Yoga may improve quality of life and vasomotor symptom domain, though evidence for direct hot flash reduction is mixed, as reported by the National Comprehensive Cancer Network 12

The American College of Physicians recommends against using custom-compounded bioidentical hormones, as there is no data to support claims of superior safety or efficacy compared to standard hormone therapies 14
The North American Menopause Society advises against delaying treatment, as menopausal symptoms remain substantially undertreated, yet effective options exist that can significantly improve quality of life 12, 13